

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;"></td> </tr> <tr> <td>Filing Date</td> <td>March 4, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Antonito Panganiban</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>960296.98849</td> </tr> </table>		Application Number		Filing Date	March 4, 2002	First Named Inventor	Antonito Panganiban	Group Art Unit		Examiner Name		Attorney Docket Number	960296.98849
Application Number															
Filing Date	March 4, 2002														
First Named Inventor	Antonito Panganiban														
Group Art Unit															
Examiner Name															
Attorney Docket Number	960296.98849														
Sheet	2	of	2												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Ww		S. Bour, et al., "The-Human Immunodeficiency Virus Type 1 Vpu Protein Specifically Binds to the Cytoplasmic Domain of CD4: Implications for a Mechanism of Degradation," J. Virol. 69:1510-1520 1995	
		M.A. Callahan, et al., "Functional Interaction of Human Immunodeficiency Virus Type 1 Vpu and Gag with a Novel Member of the Tetrapeptide Repeat Protein Family," J. Virol. 72(5):5180-5187 1998	
		R.J. Geraghty, et al., "Cell Type-dependence for Vpu Function," J. Med. Primatol. 23:146-150, 1994.	
		Y.-H. Lee, et al., "The HIV-1 Matrix Domain of Gag is Required for Vpu Responsiveness During Particle Release," Virology 237:46-55, 1997.	
		M.S. McBride, et al., "Position Dependence of Functional Hairpins Important for Human Immunodeficiency Virus Type 1 RNA Encapsidation In Vivo," J. Virol. 71(3):2050-2058, 1997	
		M.S. McBride, et al., "Efficient Encapsidation of Human Immunodeficiency Virus Type 1 Vectors and Further Characterization of cis Elements Required for Encapsidation," <i>Journal of Virology</i> 71(6):4544-4554 1997	
v		M.D. Schwartz, et al., "Distinct Functions and Requirements for the Cys-His Boxes of the Human Immunodeficiency Virus Type 1 Nucleocapsid Protein during RNA Encapsidation and Replication," J. Virol. 71(12):9295-9305. 1997.	

Examiner Signature <i>Ww</i>	Date Considered <i>1/14/04</i>
------------------------------	--------------------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.